{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:50:57Z","timestamp":1782791457765,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous pemphigoid (BP) is the most common autoimmune bullous disease. It is characterized by the development of tense blisters and pruritus. BP is a chronic disease that requires long-term treatment often associated with serious side effects. Developments in understanding the disease have led to novel treatment approaches evaluated in clinical trials. However, the pooling of trial data remains challenging due to inconsistent outcome reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide an overview of BP outcome measurement over the last two decades by mapping and listing all previously reported treatment outcomes and outcome measurement instruments (OMIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A large scoping review was performed using scientific databases and trial registries (January 2002\u2013August 2025). Study selection and data extraction were performed independently by a minimum of two reviewers. Eligible study designs were clinical trials, prospective cohort studies and systematic reviews. Retrospective studies were excluded. All identified outcomes and OMIs were mapped into overarching domains for insights into outcome measurement trends over time, including the uptake of consensus definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty studies were included, consisting of clinical trials (n = 27), prospective cohort studies (n = 27) and systematic reviews (n = 26). A total of 659 outcomes were extracted verbatim and classified into 46 outcome domains across 10 outcome domain areas. Clinical response, safety and immunological response comprised a major part of outcome measurement. Moreover, steroid toxicity has increasingly been considered in clinical trials. Definitions and timepoints of clinical response varied considerably. An imbalance between patient-reported (PROs) and clinician-reported outcomes was revealed, with PROs being in the minority, as well as a diverging focus between primary analyses in clinical trials and secondary analyses in systematic reviews. OMIs used to measure patient impact and quality of life were mainly generic and only sparsely used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over the past two decades, there has been considerable heterogeneity in reported outcomes and OMIs in BP research. Despite standardization efforts, most studies lack well-defined, consistent outcomes. Redefinition of some endpoints and a consensus-based approach towards outcome uniformity should bridge regulatory requirements with validated sensitive measurement and PROs. This approach would enhance the clinical relevance of trial endpoints while maintaining standardization, ultimately advancing research quality and therapeutic development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf471","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:04:40Z","timestamp":1763816680000},"page":"429-440","source":"Crossref","is-referenced-by-count":2,"title":["Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-1697","authenticated-orcid":false,"given":"Marjolein A J","family":"Hiel","sequence":"first","affiliation":[{"name":"Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN\u00a0SKIN), University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-010X","authenticated-orcid":false,"given":"Billal","family":"Tedbirt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de Reference des Maladies Bulleuses Autoimmunes, Normandie University , Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5654","authenticated-orcid":false,"given":"Eva W H","family":"Korte","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN\u00a0SKIN), University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-9363","authenticated-orcid":false,"given":"Maria C","family":"Bolling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN\u00a0SKIN), University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3528","authenticated-orcid":false,"given":"Joost M","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN\u00a0SKIN), University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2863","authenticated-orcid":false,"given":"Phyllis I","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam UMC, Academic Medical Center, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Public Health, Infection and Immunity, Academic Medical Center, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-7657","authenticated-orcid":false,"given":"Sjoukje","family":"van der Werf","sequence":"additional","affiliation":[{"name":"Medical Library, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6722-3569","authenticated-orcid":false,"given":"Marc","family":"Yale","sequence":"additional","affiliation":[{"name":"International Pemphigus and Pemphigoid Foundation , Roseville, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-0255","authenticated-orcid":false,"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de Reference des Maladies Bulleuses Autoimmunes, Normandie University , Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-3674","authenticated-orcid":false,"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN\u00a0SKIN), University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2026021806345968000_ljaf471-B1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"2026021806345968000_ljaf471-B2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026021806345968000_ljaf471-B3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1590\/abd1806-4841.20164935","article-title":"Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study","volume":"91","author":"Kouris","year":"2016","journal-title":"An Bras Dermatol"},{"key":"2026021806345968000_ljaf471-B4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.5598","article-title":"Mixed individual-\u00adaggregate data on all-cause mortality in bullous pemphigoid: a meta-\u00adanalysis","volume":"157","author":"Tedbirt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026021806345968000_ljaf471-B5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2\u2005K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2026021806345968000_ljaf471-B6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026021806345968000_ljaf471-B7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdin.2022.07.005","article-title":"Side effects of steroid-\u00adsparing agents in patients with bullous pemphigoid and pemphigus: a systematic review","volume":"9","author":"Zeng","year":"2022","journal-title":"JAAD Int"},{"key":"2026021806345968000_ljaf471-B8","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.jid.2023.03.1673","article-title":"The importance of patient-focused drug development in pemphigus and pemphigoid","volume":"143","author":"Yale","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026021806345968000_ljaf471-B9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in bullous pemphigoid treatment: a comprehensive pipeline update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026021806345968000_ljaf471-B10","doi-asserted-by":"crossref","first-page":"102799","DOI":"10.1016\/j.amsu.2021.102799","article-title":"A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions","volume":"70","author":"Khalid","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"2026021806345968000_ljaf471-B11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"2026021806345968000_ljaf471-B12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","article-title":"How to select outcome measurement instruments for outcomes included in a \u201cCore Outcome Set\u201d \u2013 a practical guideline","volume":"17","author":"Prinsen","year":"2016","journal-title":"Trials"},{"key":"2026021806345968000_ljaf471-B13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2026021806345968000_ljaf471-B14","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid","author":"Kirtschig","year":"2010; 2010:002292","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021806345968000_ljaf471-B15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2026021806345968000_ljaf471-B16","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026021806345968000_ljaf471-B17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026021806345968000_ljaf471-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2026021806345968000_ljaf471-B19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/bjd\/ljad077","article-title":"Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization","volume":"189","author":"Korte","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026021806345968000_ljaf471-B20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.12.020","article-title":"A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery","volume":"96","author":"Dodd","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2026021806345968000_ljaf471-B21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/XEB.0000000000000277","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"19","author":"Peters","year":"2021","journal-title":"JBI Evid Implement"},{"key":"2026021806345968000_ljaf471-B22","doi-asserted-by":"publisher","volume-title":"JBI Manual for Evidence Synthesis","author":"Peters","DOI":"10.46658\/JBIRM-19-01"},{"key":"2026021806345968000_ljaf471-B23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026021806345968000_ljaf471-B24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J\u00a0Med Libr Assoc"},{"key":"2026021806345968000_ljaf471-B25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026021806345968000_ljaf471-B26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2019.06.016","article-title":"A systematic review of core outcome set development studies demonstrates difficulties in defining unique outcomes","volume":"115","author":"Young","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2026021806345968000_ljaf471-B27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1398-9995.2012.02874.x","article-title":"Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting","volume":"67","author":"Schmitt","year":"2012","journal-title":"Allergy"},{"key":"2026021806345968000_ljaf471-B28","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","volume":"8","author":"Singh","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021806345968000_ljaf471-B29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2478\/fon-2020-0024","article-title":"Topical use of ozone effectively alleviates the acute symptoms and quality of life of patients with moderate to severe bullous pemphigoid: a randomized controlled trial","volume":"8","author":"Li","year":"2021","journal-title":"Front Nurs"},{"key":"2026021806345968000_ljaf471-B30","author":"International Pemphigus & Pemphigoid Foundation"},{"key":"2026021806345968000_ljaf471-B31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026021806345968000_ljaf471-B32","first-page":"adv00320","article-title":"Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study","volume":"100","author":"Briand","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026021806345968000_ljaf471-B33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"2026021806345968000_ljaf471-B34","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026021806345968000_ljaf471-B35","doi-asserted-by":"crossref","first-page":"adv00559","DOI":"10.2340\/00015555-3884","article-title":"Patient-Reported outcome measures in dermatology: a systematic review","volume":"101","author":"Pattinson","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2026021806345968000_ljaf471-B36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/jdv.19903","article-title":"Patient prioritisation of items to develop the Patient-Reported Impact of Dermatological Diseases measure: a global Delphi study","volume":"38","author":"Trialonis-Suthakharan","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026021806345968000_ljaf471-B37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/bjd\/ljad140","article-title":"The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership","volume":"189","author":"Harman","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026021806345968000_ljaf471-B38","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s11136-015-0965-z","article-title":"Reliability of the Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire in the USA","volume":"24","author":"Sebaratnam","year":"2015","journal-title":"Qual Life Res"},{"key":"2026021806345968000_ljaf471-B39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00403-018-1817-9","article-title":"BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid","volume":"310","author":"Daneshpazhooh","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"2026021806345968000_ljaf471-B40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"Hebert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026021806345968000_ljaf471-B41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bjd.19173","article-title":"Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores","volume":"183","author":"Ferries","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026021806345968000_ljaf471-B42","doi-asserted-by":"crossref","first-page":"1243581","DOI":"10.3389\/fimmu.2023.1243581","article-title":"Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases","volume":"14","author":"Tseng","year":"2023","journal-title":"Front Immunol"},{"key":"2026021806345968000_ljaf471-B43","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jaad.2022.04.042","article-title":"Shifting focus from \u201cwhat we do\u201d to the \u201cimpact of what we do\u201d: application of outcome measures to routine clinical care in dermatology","volume":"87","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026021806345968000_ljaf471-B44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026021806345968000_ljaf471-B45","doi-asserted-by":"crossref","first-page":"111277","DOI":"10.1016\/j.jclinepi.2024.111277","article-title":"Study found increasing use of core outcome sets in Cochrane systematic reviews and identified facilitators and barriers","volume":"169","author":"Saldanha","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026021806345968000_ljaf471-B46","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT\u2013Outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"2026021806345968000_ljaf471-B47","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/jama.2022.21243","article-title":"Guidelines for reporting outcomes in trial protocols: the SPIRIT\u2013Outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"2026021806345968000_ljaf471-B48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjd.16273","article-title":"By using a core outcome set we measure what matters to patients","volume":"178","author":"Prinsen","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026021806345968000_ljaf471-B49","doi-asserted-by":"crossref","first-page":"111307","DOI":"10.1016\/j.jclinepi.2024.111307","article-title":"Core outcome set developers should consider and specify the level of granularity of outcome domains","volume":"169","author":"Kottner","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026021806345968000_ljaf471-B50","doi-asserted-by":"crossref","first-page":"107031","DOI":"10.1016\/j.ejps.2025.107031","article-title":"Therapeutic potential of recombinant human type XVII collagen in wound healing and bullous pemphigoid: from bench to bedside","volume":"207","author":"Wang","year":"2025","journal-title":"Eur J Pharm Sci"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf471\/65502578\/ljaf471.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/3\/429\/65502578\/ljaf471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/3\/429\/65502578\/ljaf471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:35:13Z","timestamp":1771414513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/3\/429\/8342760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf471","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,25]]}}}